title: [Alzheimer's disease: therapeutic perspectives].
abstract: Current treatments for Alzheimer's disease aim to compensate for biochemical deficits in the brain. They are purely symptomatic and restore the central cholinergic deficit. Acetylcholinesterase inhibitors have modest but significant efficacy on cognitive disorders, activities of daily living, and the global clinical impression. Glutaminergic receptor antagonists are used for more advanced forms. Future treatments may be curative, acting specifically on the amyloid cascade. Secretase inhibitors and immunotherapy are in the pipeline. Trials will begin within a few months and will open up new perspectives.
authors.affiliation: Centre des Maladies Cognitives et Comportementales et Inserm U 610, Hôpital de la Salpêtrière, 47, boulevard de l'Hôpital, 75013 Paris.
authors.forename: Bruno
authors.initials: B
authors.lastname: Dubois
authors.forename: Leonardo
authors.initials: L
authors.lastname: De Souza
authors.forename: Gilles
authors.initials: G
authors.lastname: Allali
authors.forename: Michel
authors.initials: M
authors.lastname: Kalafat
authors.forename: Marie
authors.initials: M
authors.lastname: Sarazin
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy / Q000628:therapy*; D023582:Alzheimer Vaccines / Q000627:therapeutic use; D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors; D016229:Amyloid beta-Peptides / Q000627:therapeutic use; D016564:Amyloid beta-Protein Precursor / Q000378:metabolism; D000818:Animals; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D016503:Drug Delivery Systems; D004353:Drug Evaluation, Preclinical; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D018697:Nootropic Agents / Q000627:therapeutic use; D010446:Peptide Fragments / Q000627:therapeutic use; D017470:Receptors, Glutamate / Q000187:drug effects; D016875:tau Proteins / Q000037:antagonists & inhibitors
chemical_list: C437846:AN-1792; D023582:Alzheimer Vaccines; D016229:Amyloid beta-Peptides; D016564:Amyloid beta-Protein Precursor; D002800:Cholinesterase Inhibitors; D018691:Excitatory Amino Acid Antagonists; C054369:MAPT protein, human; D018697:Nootropic Agents; D010446:Peptide Fragments; D017470:Receptors, Glutamate; C075222:amyloid beta-protein (1-42); D016875:tau Proteins; D053829:Amyloid Precursor Protein Secretases